And platinum medicine next-generation all-human anti-CTLA-4 antibody HBM4003 first patient has been successfully enrolled in the group medication

recently, and platinumMedicine sin pharmaceutical(http://announced that its new generation of all-human anti-CTLA-4 antibody HBM4003 has launched the first global clinicaltrial(http://for patients with advanced solid tumors, the first patient has successfully entered the drugabout HBM4003
HBM4003 is the world's first human-derived heavy-chain antibody to enter the clinical research phase, produced from and platinum medicine-specific HCAb all-human antibody technology platformHBM4003 demonstrates its great potential in anti-tumor and safety by enhancing the cytotoxic action (ADCC) of antibody dependence on cell-mediated cells and shortening the half-life of antibodiesCompared to the first generation of anti-CTLA-4 antibodies, HBM4003 showed stronger anti-tumor activity and lower systemdrug(http://exposure in preclinical studies, indicating that it may have significant improvement in clinical efficacyand Platinum Pharmaceuticals presented the preclinical findings of HBM4003 at the American Association for Cancer Research's Annual Meeting (AACR) in April 2019currently in this clinical trial to assess the safety, pharmacokinetic characteristics and initial anti-tumor activity of HBM4003 in patients with advanced solid tumors